Evidence map›Paper›PMID 36105681›Full record

ArticleMediators of inflammation2022

miR-559 Inhibits Proliferation, Autophagy, and Angiogenesis of Hepatocellular Carcinoma Cells by Targeting PARD3.

Chunjing Wang, Chengcheng Li, Rui Hao

Open access · goldAbstract read
In one paragraph

Article in Mediators of inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chunjing WangDepartment of Gastroenterology, Affiliated Hospital of Beihua University, Jilin, Jilin Province 132000, China.ORCID https://orcid.org/0000-0001-6379-5806
Chengcheng LiDepartment of Graduate Student, Affiliated Hospital of Beihua University, Jilin, Jilin Province 132000, China.ORCID https://orcid.org/0000-0002-0697-1401
Rui HaoDepartment of Infectious Liver Disease, Affiliated Hospital of Beihua University, Jilin, Jilin Province 132000, China.ORCID https://orcid.org/0000-0003-0031-8185
Beihua University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and has a high mortality rate. Although prevention and treatment of HCC has improved, it still faces poor prognosis and high mortality. miRNAs play a critical role in the tumorigenesis of HCC, but the underlying mechanism has not been well investigated. Here, the functions and interaction between miR-559 and PARD3 were investigated in HCC cells. Increased PARD3 and decreased miR-559 expression were observed in HCC cells compared with those in normal liver cells, especially in Huh-7 cells. Studies further demonstrated that PARD3 silencing or miR-559 overexpression impaired the proliferation, autophagy, and angiogenesis in Huh-7 cells. Mechanistically, PARD3 represents a target of miR-559. Furthermore, investigations revealed that miR-559 inhibition induced the expression of PARD3, thereby enhancing cell proliferation, autophagy, and angiogenesis in Huh-7 cells. These results reveal the interaction between miR-559 and PARD3 in HCC cells and provide new insights into their potential targets as therapeutic treatment against HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsAdaptor Proteins, Signal TransducingAutophagyCell Cycle ProteinsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansAdaptor Proteins, Signal TransducingCell Cycle ProteinsMicroRNAsMIRN559 microRNA, humanPARD3 protein, human

Identifiers

PMID36105681
PMCPMC9467804
OpenAlexW4295899942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.